Administrative expenses also include professional fees for legal, patent, consulting, accounting, tax and audit services, travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities, technology, and other operating costs.

filing / Apr 24, 2026 / receipt

Peter Lin has served as our Chief Financial Officer since September 2025. Mr. Lin (CAIA, MBA, MIS) is a seasoned corporate executive and investor with a distinguished career spanning biotechnology, finance, and private equity.

filing / Apr 24, 2026 / receipt

in active clinical program expenditure due to a more narrow development focus, $(4.7) million decrease in employee other compensation and benefits due to R&D employee reductions in the second half of 2024 to reduce expenses, and a $(3.4) million decrease in employee share-based compensation mainly from employee departures in 2024 and 2025.

filing / Apr 24, 2026 / receipt

reductions in the second half of 2024 to reduce expenses, and a $(1.6) million decrease in employee share-based compensation mainly from the aforementioned employee reductions in the second half of 2024.

filing / Apr 24, 2026 / receipt

These operating subsidiaries conduct R&D activities relating to the biologics of oncology, to facilitate the discovery and development of product candidates and expand our global presence.

filing / Apr 24, 2026 / receipt

In China, we previously leased an office facility in Hangzhou; however, as part of our cost-reduction and operational restructuring initiatives in April 2025, we terminated this lease and transitioned to a flexible co-working space arrangement.

filing / Apr 24, 2026 / receipt

Administrative expenses also include professional fees for legal, patent, consulting, accounting, tax and audit services, travel expenses and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities, technology, and other operating costs.

filing / Apr 24, 2026 / receipt

Peter Lin has served as our Chief Financial Officer since September 2025. Mr. Lin (CAIA, MBA, MIS) is a seasoned corporate executive and investor with a distinguished career spanning biotechnology, finance, and private equity.

filing / Apr 24, 2026 / receipt

in active clinical program expenditure due to a more narrow development focus, $(4.7) million decrease in employee other compensation and benefits due to R&D employee reductions in the second half of 2024 to reduce expenses, and a $(3.4) million decrease in employee share-based compensation mainly from employee departures in 2024 and 2025.

filing / Apr 24, 2026 / receipt

reductions in the second half of 2024 to reduce expenses, and a $(1.6) million decrease in employee share-based compensation mainly from the aforementioned employee reductions in the second half of 2024.

filing / Apr 24, 2026 / receipt

These operating subsidiaries conduct R&D activities relating to the biologics of oncology, to facilitate the discovery and development of product candidates and expand our global presence.

filing / Apr 24, 2026 / receipt

In China, we previously leased an office facility in Hangzhou; however, as part of our cost-reduction and operational restructuring initiatives in April 2025, we terminated this lease and transitioned to a flexible co-working space arrangement.

filing / Apr 24, 2026 / receipt